- Home
- MAS vs OKUR Comparison
MAS vs OKUR Comparison
Compare MAS & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAS
- OKUR
- Stock Information
- Founded
- MAS 1929
- OKUR 2011
- Country
- MAS United States
- OKUR United States
- Employees
- MAS N/A
- OKUR N/A
- Industry
- MAS Industrial Specialties
- OKUR
- Sector
- MAS Industrials
- OKUR
- Exchange
- MAS Nasdaq
- OKUR NYSE
- Market Cap
- MAS 12.9B
- OKUR 34.9M
- IPO Year
- MAS N/A
- OKUR N/A
- Fundamental
- Price
- MAS $66.59
- OKUR $2.40
- Analyst Decision
- MAS Buy
- OKUR Strong Buy
- Analyst Count
- MAS 13
- OKUR 4
- Target Price
- MAS $72.65
- OKUR $32.25
- AVG Volume (30 Days)
- MAS 2.3M
- OKUR 71.2K
- Earning Date
- MAS 07-31-2025
- OKUR 08-14-2025
- Dividend Yield
- MAS 1.84%
- OKUR N/A
- EPS Growth
- MAS N/A
- OKUR N/A
- EPS
- MAS 3.66
- OKUR N/A
- Revenue
- MAS $7,703,000,000.00
- OKUR N/A
- Revenue This Year
- MAS N/A
- OKUR N/A
- Revenue Next Year
- MAS $4.05
- OKUR N/A
- P/E Ratio
- MAS $18.13
- OKUR N/A
- Revenue Growth
- MAS N/A
- OKUR N/A
- 52 Week Low
- MAS $56.55
- OKUR $1.70
- 52 Week High
- MAS $86.70
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- MAS 63.57
- OKUR N/A
- Support Level
- MAS $63.69
- OKUR N/A
- Resistance Level
- MAS $68.54
- OKUR N/A
- Average True Range (ATR)
- MAS 1.40
- OKUR 0.00
- MACD
- MAS 0.57
- OKUR 0.00
- Stochastic Oscillator
- MAS 81.70
- OKUR 0.00
About MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5-billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The $3-billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware and lighting products.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.